. 2018 Oct 2;6(4):85. doi: 10.3390/medsci6040085

Table 3.

Subdivision of glioblastomas in molecular subgroups according to the presence of TERT abnormalities (including TERT promoter mutations, TERTp^mut and TERT gene structural variants, TERT^SV), IDH1 or IDH2 mutations (IDH^mut) and the presence of genetic abnormalities conferring an alternative lengthening of telomeres (ALT) phenotype in the presence of a TERTp^WT (TERTp^WT-ALT).

Tumor Subtype	Main Genetic and Chromosomal Abnormalities	Prognosis
IDH^WT-TERT^SV	EGFR, PTEN, TP53, and PPM1D mutations; Loss of CDKN2A/B; PDGFRA amplification. Loss of chromosome 4; gain of chromosome 7 and 19.	Poor
IDH^WT-TERTp^WT-ALT	ATRX, SMARCAL1, NF1, and BRAF mutations Loss of chromosome 4; gain of chromosome 7 and 19.	Poor
IDH^WT-TERTp^mut	TERT, EGFR, EGFRvIII, NF1, PTEN, RB1, PIK3CA, And PIK3R1 mutations; amplification of EGFR; Deletion of PTEN; loss of CDKN2A/B (homozygous) Loss of chromosome 4; gain of chromosome 7 and 19.	Poor
IDH^mut-TERTp^WT	IDH1 or IDH2, TP53 and ATRX mutations. Duplication of 7q, duplication of 8q24, loss of CDKN2/B (hemizygous), deletion of 19q.	Better
IDH^mut-TERTp^mut	TERTp, IDH1, or IDH2, TP53 and ATRX mutations. Gain of chromosome 7, duplication of 8q24, loss of CDKN2A/B (hemizygous), deletion of PTEN.	Better